Insight Molecular DiagnosticsIMDX -3.23%49 PS Ratio is 88.52 as of Jun. 27, 2026, which is 118% above its 10-year median of 40.53. GuruFocus rates IMDX with a GF Score™ of 49/100 and a GF Value™ of $1.26 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 201 Medical Diagnostics & Research companies, Insight Molecular Diagnostics ranks worse than 96.52% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Insight Molecular Diagnostics's share price is $5.40.
Insight Molecular Diagnostics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.06. Hence, Insight Molecular Diagnostics's PS Ratio for today is 88.52.
The historical rank and industry rank for Insight Molecular Diagnostics's PS Ratio or its related term are showing as below:
IMDX'
s PS Ratio Range Over the Past 10 Years
Min: 11.12 Med: 40.53 Max: 13480
Current: 88.52
During the past 13 years, Insight Molecular Diagnostics's highest PS Ratio was 13480.00. The lowest was 11.12. And the median was 40.53.
IMDX's PS Ratio is ranked worse than 96.52% of 201
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.78
vs IMDX: 88.52
During the past 13 years, Insight Molecular Diagnostics's highest 3-Year average Revenue per Share Growth Rate was -8.40% per year. The lowest was -33.70% per year. And the median was -19.20% per year.
Back to Basics: PS Ratio
Insight Molecular Diagnostics (NAS:IMDX) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Insight Molecular Diagnostics PS Ratio Related Terms
Insight Molecular Diagnostics PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Insight Molecular Diagnostics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Insight Molecular Diagnostics PS Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Insight Molecular Diagnostics's PS Ratio distribution charts can be found below:
* The bar in red indicates where Insight Molecular Diagnostics's PS Ratio falls into.
Insight Molecular Diagnostics PS Ratio Calculation
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Insight Molecular Diagnostics's Share Price of today is $5.40. Insight Molecular Diagnostics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.06.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Insight Molecular Diagnostics (IMDX) has a PS Ratio of 88.52 as of Jun. 27, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Insight Molecular Diagnostics and its competitors. This is 118% above median its historical median of 40.53. Over the past decade, Insight Molecular Diagnostics' PS Ratio has ranged from 11.12 to 13,480.00. According to the industry distribution chart, Insight Molecular Diagnostics ranks #194 out of 201 companies in the Medical Diagnostics & Research industry, placing it in the top 96.5%.
Is Insight Molecular Diagnostics' PS Ratio too high?
Insight Molecular Diagnostics' current PS Ratio of 88.52 is 118% above median its 10-year median of 40.53. Over the past 10 years, this metric has ranged from a low of 11.12 to a high of 13,480.00. The Medical Diagnostics & Research industry median PS Ratio is 2.78. Insight Molecular Diagnostics' value of 88.52 is 3084.2% above this industry median. Based on the distribution chart, Insight Molecular Diagnostics ranks #194 out of 201 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Insight Molecular Diagnostics has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Insight Molecular Diagnostics' PS Ratio compare to BDSX and XGN?
According to the Medical Diagnostics & Research industry distribution chart, Insight Molecular Diagnostics ranks #194 out of 201 companies for PS Ratio. This places Insight Molecular Diagnostics in the lower half of its industry. The industry median PS Ratio is 2.78. Insight Molecular Diagnostics' value of 88.52 is 3084.2% above this benchmark. Historically, Insight Molecular Diagnostics' own PS Ratio has ranged from 11.12 to 13,480.00 over the past decade. While the company's 10-year median is 40.53 vs. the industry median of 2.78, Insight Molecular Diagnostics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Diagnostics & Research company?
The median PS Ratio among Medical Diagnostics & Research companies is 2.78, based on 201 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Insight Molecular Diagnostics's current PS Ratio of 88.52 is 3084.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Insight Molecular Diagnostics and its competitors. For the Medical Diagnostics & Research industry, the median PS Ratio is 2.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Insight Molecular Diagnostics's current PS Ratio is 88.52, which is 118% above median its own 10-year median of 40.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Insight Molecular Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Insight Molecular Diagnostics (IMDX) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.26, compared to a current price of $5.40 — trading 328.6% above its estimated fair value. The current PS Ratio is 88.52, which is 118% above median its 10-year median of 40.53 and 3084.2% above the Medical Diagnostics & Research industry median of 2.78. Insight Molecular Diagnostics' overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Insight Molecular Diagnostics (IMDX), the current PS Ratio is 88.52 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Insight Molecular Diagnostics (IMDX) Overvalued in 2026?
Based on GuruFocus' analysis, Insight Molecular Diagnostics stock appears to be overvalued.
The current stock price of $5.40 is trading 328.6% above its estimated GF Value™ of $1.26.
GuruFocus considers Insight Molecular Diagnostics to be Significantly Overvalued.
Key valuation signals for IMDX:
PS Ratio: 88.52 (118% above median its 10-year median of 40.53)
GF Value™: $1.26 vs. price of $5.40 (328.6% above fair value)
Industry Position: 3084.2% above the Medical Diagnostics & Research median (#194 of 201)
No single metric tells the full story. See the IMDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Insight Molecular Diagnostics Business Description
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. The company geographically operates in the United States, the United Kingdom, Europe, and the Asia-Pacific regions, with maximum revenue generated from the USA.
49GF Score
Get the complete analysis for IMDX
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IMDX has been successfully added to your 
